Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment.
Journal: JHEP reports : innovation in hepatology
Published: June 12, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: March 14, 2025
Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib.
Journal: Journal of the advanced practitioner in oncology
Published: January 10, 2024
Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series.
Journal: Annals of translational medicine
Published: November 18, 2023
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Journal: Cancer
Published: June 29, 2023
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.
Journal: Journal of vascular and interventional radiology : JVIR
Published: June 22, 2023
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
Journal: Liver cancer
Published: May 19, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Journal: Investigational new drugs
Published: March 01, 2023
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
Journal: Journal for immunotherapy of cancer
Published: May 13, 2022
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: August 31, 2021
Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Journal: Abdominal radiology (New York)
Published: August 23, 2021
Last Updated: 09/26/2026